Best Practices and Research Advances in Thoracic Oncology: A Regional Series MENA Course 1: Liquid Biopsy in Lung Cancer-Precision Oncology for Every Community

Video Transcription

Video Summary

The webinar discusses the importance of precision oncology, emphasizing its role in tailoring cancer treatments to individual patients based on their specific genetic mutations, particularly focusing on non-small cell lung cancer (NSCLC). The speaker highlights how precision oncology allows for better treatment outcomes by identifying targetable genetic mutations, such as EGFR, ALK, and KRAS, enabling the use of FDA-approved targeted therapies. The presentation underscores the significance of biomarker testing in accordance with national and international guidelines to guide treatment decisions. It also stresses the advantage of using liquid biopsies for genetic testing due to their minimally invasive nature and quicker results, which are crucial for timely therapeutic decisions.<br /><br />The discussion further explores the integration of liquid and tissue biopsies to enhance detection of mutations and resistance mechanisms, ensuring optimal patient care. Additionally, the video stresses the need for local solutions, such as establishing laboratories for timely and accurate genetic testing, and maintaining data on genetic mutation prevalence to inform treatment strategies and clinical trials in different regions. The talk concludes by advocating for ongoing validation of laboratory results to ensure effective implementation in clinical practice.

Asset Subtitle

Nagla Abdel Karim, MD, PhD

Keywords

precision oncology

non-small cell lung cancer

genetic mutations

biomarker testing

liquid biopsies

targeted therapies

clinical practice